Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3728921 | 0.87 | MTNR1A (0.62) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL3250424 | 0.87 | NR4A1 (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL930493 | 0.86 | MTNR1A (0.61) | MTNR1AMTNR1BALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL14338249 | 0.86 | MTNR1B (0.69) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL9162294 | 0.84 | MTNR1B (0.77) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL13041371 | 0.84 | ALDH1A1 (0.55) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL5345460 | 0.83 | MEN1 (0.61) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL14375415 | 0.83 | MEN1 (0.61) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL12888865 | 0.83 | MAPK1 (0.65) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL3728925 | 0.82 | ALDH1A1 (0.56) | MTNR1AMTNR1BALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040082583-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249600-A1 | CHEMICAL COMPOUNDS | TIE1, KDR, FLT4 | MTNR1A 2937/4885MTNR1B 1843/4885ALDH1A1 955/4885 |
| US-20040082583-A1 | Chemical compounds | TIE1, KDR, FLT4 | MTNR1A 2937/4885MTNR1B 1843/4885ALDH1A1 955/4885 |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | MTNR1A 1396/4885MTNR1B 982/4885ALDH1A1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.